Log in to save to my catalogue

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed...

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6d2eb34905f7419ca7f3a7451cc9953e

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

About this item

Full title

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

Publisher

London: BMJ Publishing Group LTD

Journal title

Journal for immunotherapy of cancer, 2023-08, Vol.11 (8), p.e007118

Language

English

Formats

Publication information

Publisher

London: BMJ Publishing Group LTD

More information

Scope and Contents

Contents

BackgroundBrexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved in the USA for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and in the European Union for patients ≥26 years with R/R B-ALL. After 2 years of follow-up in ZUMA-3, the overall comp...

Alternative Titles

Full title

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_6d2eb34905f7419ca7f3a7451cc9953e

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6d2eb34905f7419ca7f3a7451cc9953e

Other Identifiers

ISSN

2051-1426

E-ISSN

2051-1426

DOI

10.1136/jitc-2023-007118

How to access this item